One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant.

Lindsey Chippendale,Craig W Freyer,Alison Carulli,Daria V Babushok,Noelle V Frey,Saar I Gill,Elizabeth O Hexner,Selina M Luger,Mary Ellen Martin,David L Porter,Edward A Stadtmauer,Alison W Loren

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners（2023）

引用 0|浏览11

暂无评分

摘要

We observed no significant difference in alloHCT outcomes between patients who underwent one versus two sets of busulfan TDM sampling, suggesting that a single-time TDM and dose adjustment may be adequate to maximize outcomes after MAC alloHCT.

查看译文

关键词

Allogeneic hematopoietic cell transplant,Busulfan,Busulfan pharmacokinetics,Therapeutic drug monitoring

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要